Incidence and long-term course of subclinical and clinical myocardial damage as well as pulmonary vascular and structural changes in patients with COVID-19

Conditions: U07.1
COVID-19, virus identified

Registration Number: DRKS00021727

Lead Sponsor: niversitätsherzzentrum Freiburg Bad Krozingen

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 100

Inclusion Criteria

PCR-secured SARS-CoV-2 infection
- Clinically manifest signs of SARS-CoV-2 infection
- Ability / willingness to come to the 6-month follow-up

Exclusion Criteria

- Missing written informed consent
- Contraindication for MRI examination according to the current guidelines (e.g. metal implants, severe allergy to MRI contrast media)
- severe renal failure (creatinine clearance <30ml / min / 1.73m2)
- People who are in a dependency or employment relationship with the clinic or examiner stand
- Placement in an institution based on a judicial or official order
- Demential development or other illness (e.g. substance abuse) that a Understanding of the clarification in the study and / or a legally effective clarification makes unlikely.
- pregnancy

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
eft and right ventricular ejection fraction (echo and MRI) at the time of inpatient treatment for Sars-CoV2 infection and after 6 months

Secondary Outcome Measures

Name	Time	Method
• Markers for myocardial damage that are not detected by a decrease in the ejection fraction (including blood: highly sensitive troponin T, NT-proBNP / ECG: QRS fragmentation / echo: myocardial strain, pulmonary arterial pressure / MRI: late enhancement ) at the time of inpatient treatment for Sars-CoV2 infection and after 6 months<br>• Cardiovascular event rate within 12 months (death, myocardial infarction, hospitalization for heart failure)